http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2545575-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8925b769d645f9ff06af9f4b189f6a99 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6935 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6921 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate | 2004-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3142cdb293f14ec9ea87adfa2c004b2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_778e3f534499f83221fb1dd42137b13c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fd32f8ff799977cf6f0766334ac6144 |
| publicationDate | 2005-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2545575-A1 |
| titleOfInvention | Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof |
| abstract | The present invention relates to novel pharmaceutical formulations for base of stable and fluid aqueous colloidal suspensions for release prolonged interleukin -IL- (and one or more other principle (s) s), as well as the applications, in particular the therapeutic ones, of these formulations. The purpose of the invention is to propose a formulation pharmaceutical formulation for the sustained release of interleukin (s) (and one or several other possible active principle (s), allowing after injection parenterally significantly increase the duration of vivo, while decreasing the peak plasma concentration of this IL, said formulation must also be stable to the preservation and in addition biocompatible, biodegradable non-toxic, non-immunogenic and well tolerated locally. The formulation according to the invention is a suspension aqueous colloidal material of low viscosity, submicron particles of biodegradable PO polymer, water-soluble and bearing hydrophobic groups (GH), which particles are non-covalently associated with less one interleukin (and one or more other active ingredient (s) possible) and forming a gelled deposit at the injection site, this gelation being caused by a protein present in the medium physiological. |
| priorityDate | 2003-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 259.